Exclusive
scalehealthtech Realize your Healthcare’s Digital Transformation journey with ScaleHealthTech Learn More

Alphabet's Isomorphic Labs to Begin Clinical Trials for AI-Designed Drugs in 2025

Written by : Jayati Dubey

January 25, 2025

Category Img

Source: X (twitter)

CEO Hassabis added that the company aims to drastically shorten the drug discovery timeline, which traditionally spans a decade or more, to just "weeks or months."

Isomorphic Labs, a spinoff of Google's DeepMind, is set to take a significant leap in healthcare innovation by initiating clinical trials for drugs designed using artificial intelligence (AI) this year, according to CEO Demis Hassabis.

Speaking at the World Economic Forum in Davos, Hassabis announced, "We’ll hopefully have some AI-designed drugs in clinical trials by the end of the year. That’s the plan."

Hassabis added that the company aims to drastically shorten the drug discovery timeline, which traditionally spans a decade or more, to just "weeks or months."

This ambitious goal is fueled by Isomorphic’s groundbreaking AI advancements, including AlphaFold 3.

The model enables scientists to predict the 3D structures of biomolecular complexes, accelerating the identification of promising drug candidates.

Hassabis, along with DeepMind scientist John Jumper, received the 2024 Nobel Prize in Chemistry for their pioneering research in predicting protein structures.

This achievement underscores the potential of AI-driven tools like AlphaFold in revolutionizing the field of drug discovery.

Challenges in AI Adoption for Pharma

Despite its promise, AI-driven drug development faces hurdles.

A Bloomberg Intelligence report led by Andrew Galler noted that pharmaceutical companies are cautiously exploring AI, citing mixed results from preliminary data on clinical candidates.

Alphabet launched Isomorphic Labs in 2021 to commercialize DeepMind’s AI capabilities for drug discovery.

As the company prepares for its first clinical trials, it signals a promising step toward harnessing AI to transform the pharmaceutical industry.

Stay tuned for more such updates on Digital Health News.


POPULAR CATEGORIES

WEEKLY POPULAR POSTS

ABOUT US

Digital Health News ( DHN) is India’s first dedicated digital health news platform launched by Industry recognized HealthTech Leaders. DHN Is Industry’s Leading Source Of HealthTech Business, Insights, Trends And Policy News.

DHN Provides In-Depth Data Analysis And Covers Most Impactful News As They Happen Across Entire Ecosystem Including Emerging Technology Trends And Innovations, Digital Health Startups, Hospitals, Health Insurance, Govt. Agencies & Policies, Pharmaceuticals And Biotech.

CONTACT US

© Digital Health News 2025